FDA clears drug-coated stent from Abbott

07/2/2008 | Wall Street Journal, The · Bloomberg

The FDA on Wednesday approved Abbott Laboratories' Xience V drug-coated stent, which is expected to compete with Boston Scientific's Taxus and Johnson & Johnson's Cypher in the approximately $2 billion U.S. market for the devices. The clearance also allows Boston Scientific to launch Promus, a version of the Abbott-made stent.

View Full Article in:

Wall Street Journal, The · Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Fort Worth, TX
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA